Colorektales Karzinom – Besondere Aspekte in der Versorgung alter und geriatrischer Patienten

  • Nicolai Härtel
  • Gunther Klautke
  • Ulrich Ronellenfitsch
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Das Colonkarzinom ist eine der häufigsten Krebserkrankungen weltweit. Die Neuerkrankungsrate in Deutschland liegt bei über 60,000 Menschen jährlich (Thermann und Seufferlein 2010). Zudem steigt die Zahl der Neuerkrankungen mit dem Alter. So ist auch der Darmkrebs eine Erkrankung des älteren Menschen, ca. 45 % der Patienten sind ≥75 Jahre alt (Aparicio et al. 2017). Dem gegenüber steht ein Mangel an Erkenntnis über die besonderen Erfordernisse dieser Patienten. Dies betrifft u. a. den Einsatz geriatrischer Assessments in der klinischen Versorgung, die Unterrepräsentation dieser Altersgruppe in klinischen Studien, sowie das mangelnden Verständnis spezieller altersabhängiger Veränderungen, die den klinischen Verlauf von Patienten mit colorektalem Karzinom im Alter maßgeblich beeinflussen (Extermann 2005; Dale et al. 2012). Das folgende Kapitel fasst praxisnah die aktuell vorliegende Evidenz zur Therapie des colorektalen Karzinoms älterer Patienten zusammen.

Literatur

  1. Adam R, Frilling A, Elias D, Laurent C, Ramos E, Capussotti L, Poston GJ, Wicherts DA, de Haas RJ (2010) Liver resection of colorectal metastases in elderly patients. Br J Surg 97(3):366–376.  https://doi.org/10.1002/bjs.6889CrossRefPubMedGoogle Scholar
  2. Andre T (2017a) Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. J Clin Oncol 35 (suppl; abstr 3531)Google Scholar
  3. Andre T (2017b) Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: the French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol 35 (suppl; abstr 3500)Google Scholar
  4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351.  https://doi.org/10.1056/NEJMoa032709350/23/2343CrossRefPubMedGoogle Scholar
  5. Aparicio T, Gargot D, Teillet L, Maillard E, Genet D, Cretin J, Locher C, Bouche O, Breysacher G, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Auby D, Faroux R, Bachet JB, Lepere C, Khemissa F, Sobhani I, Boulat O, Mitry E, Jouve JL (2017) Geriatric factors analyses from FFCD 2001–02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. Eur J Cancer 74:98–108.  https://doi.org/10.1016/j.ejca.2016.09.029, [pii] S0959-8049(16)32475-3CrossRefPubMedGoogle Scholar
  6. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, Cretin J, Locher C, Bouche O, Breysacher G, Charneau J, Seitz JF, Gasmi M, Stefani L, Ramdani M, Lecomte T, Mitry E (2013a) Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001–02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 31(11):1464–1470.  https://doi.org/10.1200/JCO.2012.42.9894CrossRefPubMedGoogle Scholar
  7. Aparicio T, Lavau-Denes S, Phelip JM, Maillard E, Jouve JL, Gargot D, Gasmi M, Locher C, Adhoute X, Michel P, Khemissa F, Lecomte T, Provencal J, Breysacher G, Legoux JL, Lepere C, Charneau J, Cretin J, Chone L, Azzedine A, Bouche O, Sobhani I, Bedenne L, Mitry E (2016) Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02). Ann Oncol 27(1):121–127.  https://doi.org/10.1093/annonc/mdv491CrossRefPubMedGoogle Scholar
  8. Aparicio T, Schischmanoff O, Poupardin C, Soufir N, Angelakov C, Barrat C, Levy V, Choudat L, Cucherousset J, Boubaya M, Lagorce C, Guetz GD, Wind P, Benamouzig R (2013b) Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients. Dig Liver Dis 45(3):245–250.  https://doi.org/10.1016/j.dld.2012.09.013, [pii] S1590-8658(12)00371-4CrossRefPubMedGoogle Scholar
  9. Arai T, Kasahara I, Sawabe M, Honma N, Aida J, Tabubo K (2010) Role of methylation of the hMLH1 gene promoter in the development of gastric and colorectal carcinoma in the elderly. Geriatr Gerontol Int 10(Suppl 1):S207–S212.  https://doi.org/10.1111/j.1447-0594.2010.00590.xGGI590CrossRefPubMedGoogle Scholar
  10. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224–237CrossRefPubMedGoogle Scholar
  11. Beppu N, Kobayashi M, Matsubara N, Noda M, Yamano T, Doi H, Kamikonya N, Kakuno A, Kimura F, Yamanaka N, Yanagi H, Tomita N (2015) Comparison of the pathological response of the mesorectal positive nodes between short-course chemoradiotherapy with delayed surgery and long-course chemoradiotherapy in patients with rectal cancer. Int J Colorectal Dis 30(10):1339–1347.  https://doi.org/10.1007/s00384-015-2321-8CrossRefPubMedGoogle Scholar
  12. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51(10):1243–1252.  https://doi.org/10.1016/j.ejca.2015.04.007, [pii] S0959-8049(15)00311-1
  13. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48(10):1466–1475.  https://doi.org/10.1016/j.ejca.2012.02.057, [pii] S0959-8049(12)00209-2CrossRefPubMedGoogle Scholar
  14. Bonner JA (2004) Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22 (14_suppl, 5507–5507)Google Scholar
  15. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28.  https://doi.org/10.1016/S1470-2045(09)70311-0CrossRefPubMedGoogle Scholar
  16. Bujko K, Nasierowska-Guttmejer A, Wyrwicz L, Malinowska M, Krynski J, Kosakowska E, Rutkowski A, Pietrzak L, Kepka L, Radziszewski J, Olszyna-Serementa M, Bujko M, Danek A, Kryj M, Wydmanski J, Zegarski W, Markiewicz W, Lesniak T, Zygulski I, Porzuczek-Zuziak D, Bebenek M, Maciejczyk A, Polkowski W, Czeremszynska B, Cieslak-Zeranska E, Toczko Z, Radkowski A, Kolodziejski L, Szczepkowski M, Majewski A, Jankowski M (2013) Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study. Radiother Oncol 107(2):171–177.  https://doi.org/10.1016/j.radonc.2013.03.001, [pii] S0167-8140(13)00080-7CrossRefPubMedGoogle Scholar
  17. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudelko M, Kryj M, Oledzki J, Szmeja J, Sluszniak J, Serkies K, Kladny J, Pamucka M, Kukolowicz P (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 72(1):15–24.  https://doi.org/10.1016/j.radonc.2003.12.006, [pii] S0167814004000040CrossRefPubMedGoogle Scholar
  18. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Krynski J, Michalski W, Oledzki J, Kusnierz J, Zajac L, Bednarczyk M, Szczepkowski M, Tarnowski W, Kosakowska E, Zwolinski J, Winiarek M, Wisniowska K, Partycki M, Beczkowska K, Polkowski W, Stylinski R, Wierzbicki R, Bury P, Jankiewicz M, Paprota K, Lewicka M, Cisel B, Skorzewska M, Mielko J, Bebenek M, Maciejczyk A, Kapturkiewicz B, Dybko A, Hajac L, Wojnar A, Lesniak T, Zygulska J, Jantner D, Chudyba E, Zegarski W, Las-Jankowska M, Jankowski M, Kolodziejski L, Radkowski A, Zelazowska-Omiotek U, Czeremszynska B, Kepka L, Kolb-Sielecki J, Toczko Z, Fedorowicz Z, Dziki A, Danek A, Nawrocki G, Sopylo R, Markiewicz W, Kedzierawski P, Wydmanski J (2016) Long-course oxaliplatin-based preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 27(5):834–842.  https://doi.org/10.1093/annonc/mdw062CrossRefPubMedGoogle Scholar
  19. Cogdill AP, Andrews MC, Wargo JA (2017) Hallmarks of response to immune checkpoint blockade. Br J Cancer 117(1):1–7.  https://doi.org/10.1038/bjc.2017.136CrossRefPubMedPubMedCentralGoogle Scholar
  20. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14(11):1077–1085.  https://doi.org/10.1016/S1470-2045(13)70154-2CrossRefPubMedGoogle Scholar
  21. Dale JE, Sebjornsen S, Leh S, Rosler C, Aaserud S, Moller B, Fluge O, Erichsen C, Nadipour S, Korner H, Pfeffer F, Dahl O (2017) Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncol 56(1):81–87.  https://doi.org/10.1080/0284186X.2016.1244356CrossRefPubMedGoogle Scholar
  22. Dale W, Mohile SG, Eldadah BA, Trimble EL, Schilsky RL, Cohen HJ, Muss HB, Schmader KE, Ferrell B, Extermann M, Nayfield SG, Hurria A (2012) Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst 104(8):581–589.  https://doi.org/10.1093/jnci/djs145CrossRefPubMedPubMedCentralGoogle Scholar
  23. Dekker JW, Gooiker GA, Bastiaannet E, van den Broek CB, van der Geest LG, van de Velde CJ, Tollenaar RA, Liefers GJ (2014) Cause of death the first year after curative colorectal cancer surgery; a prolonged impact of the surgery in elderly colorectal cancer patients. Eur J Surg Oncol 40(11):1481–1487.  https://doi.org/10.1016/j.ejso.2014.05.010, [pii] S0748-7983(14)00468-5CrossRefPubMedGoogle Scholar
  24. Di Benedetto F, Berretta M, D’Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE (2011) Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc 59(12):2282–2290.  https://doi.org/10.1111/j.1532-5415.2011.03734.xCrossRefPubMedGoogle Scholar
  25. Diaz-Nieto R, Fenwick S, Malik H, Poston G (2017) Defining the optimal use of ablation for metastatic colorectal cancer to the liver without high-level evidence. Curr Treat Options Oncol 18(2):8.  https://doi.org/10.1007/s11864-017-0452-6CrossRefPubMedGoogle Scholar
  26. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346–1355.  https://doi.org/10.1093/annonc/mdu141CrossRefPubMedGoogle Scholar
  27. Erlandsson J, Holm T, Pettersson D, Berglund A, Cedermark B, Radu C, Johansson H, Machado M, Hjern F, Hallbook O, Syk I, Glimelius B, Martling A (2017) Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18(3):336–346.  https://doi.org/10.1016/S1470-2045(17)30086-4CrossRefPubMedGoogle Scholar
  28. Extermann M (2005) Geriatric assessment with focus on instrument selectivity for outcomes. Cancer J 11(6):474–480CrossRefPubMedGoogle Scholar
  29. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ 3rd, Balducci L (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118(13):3377–3386.  https://doi.org/10.1002/cncr.26646CrossRefPubMedGoogle Scholar
  30. Faiz O, Haji A, Bottle A, Clark SK, Darzi AW, Aylin P (2011) Elective colonic surgery for cancer in the elderly: an investigation into postoperative mortality in English NHS hospitals between 1996 and 2007. Colorectal Dis 13(7):779–785.  https://doi.org/10.1111/j.1463-1318.2010.02290.xCDI2290CrossRefPubMedGoogle Scholar
  31. Fietkau R, Rodel C, Hohenberger W, Raab R, Hess C, Liersch T, Becker H, Wittekind C, Hutter M, Hager E, Karstens J, Ewald H, Christen N, Jagoditsch M, Martus P, Sauer R (2007) Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys 67(4):1008–1019.  https://doi.org/10.1016/j.ijrobp.2006.10.020, [pii] S0360-3016(06)03349-9CrossRefPubMedGoogle Scholar
  32. Fietkau R, Zettl H, Klocking S, Kundt G (2004) Incidence, therapy and prognosis of colorectal cancer in different age groups. A population-based cohort study of the Rostock Cancer Registry. Strahlenther Onkol 180(8):478–487.  https://doi.org/10.1007/s00066-004-1260-zCrossRefPubMedGoogle Scholar
  33. Folprecht G (2010) Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (MCRC): a pooled analysis of the crystal and opus studies. Ann Oncol 21(Suppl 8):195Google Scholar
  34. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Kohne CH (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15(9):1330–1338.  https://doi.org/10.1093/annonc/mdh34415/9/1330CrossRefPubMedGoogle Scholar
  35. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25(5):1018–1025.  https://doi.org/10.1093/annonc/mdu088CrossRefPubMedGoogle Scholar
  36. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Kohne CH (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26(9):1443–1451.  https://doi.org/10.1200/JCO.2007.14.050926/9/1443CrossRefPubMedGoogle Scholar
  37. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318; discussion 318–321CrossRefPubMedPubMedCentralGoogle Scholar
  38. Francois E, Berdah JF, Chamorey E, Lesbats G, Teissier E, Codoul JF, Badetti JL, Hebert C, Mari V (2008) Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 62(6):931–936.  https://doi.org/10.1007/s00280-008-0681-2CrossRefPubMedGoogle Scholar
  39. Frasson M, Braga M, Vignali A, Zuliani W, Di Carlo V (2008) Benefits of laparoscopic colorectal resection are more pronounced in elderly patients. Dis Colon Rectum 51(3):296–300.  https://doi.org/10.1007/s10350-007-9124-0CrossRefPubMedGoogle Scholar
  40. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA (2014) Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 14:897.  https://doi.org/10.1186/1471-2407-14-897CrossRefPubMedPubMedCentralGoogle Scholar
  41. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797–1806.  https://doi.org/10.1200/JCO.2004.09.059CrossRefPubMedGoogle Scholar
  42. Hazel GA van, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodriguez J, Kroning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34(15):1723–1731.  https://doi.org/10.1200/JCO.2015.66.1181
  43. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18(9):1004–1012.  https://doi.org/10.1634/theoncologist.2013-0107CrossRefPubMedPubMedCentralGoogle Scholar
  44. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29(10):1261–1270.  https://doi.org/10.1200/JCO.2010.30.1366CrossRefPubMedGoogle Scholar
  45. Jehn CF, Boning L, Kroning H, Possinger K, Luftner D (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 106(2):274–278.  https://doi.org/10.1038/bjc.2011.554CrossRefPubMedPubMedCentralGoogle Scholar
  46. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638–646.  https://doi.org/10.1056/NEJMoa010580CrossRefPubMedGoogle Scholar
  47. Klautke G, Kuchenmeister U, Foitzik T, Ludwig K, Semrau S, Prall F, Klar E, Fietkau R (2007) Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol 85(3):379–384.  https://doi.org/10.1016/j.radonc.2007.10.042, [pii] S0167-8140(07)00551-8CrossRefPubMedGoogle Scholar
  48. Klautke G, Sauer R (2014) Neoadjuvant short-course radiotherapy followed by chemotherapy or simultaneous radiochemotherapy for local unresectable rectal cancer. Strahlenther Onkol 190(3):317–318.  https://doi.org/10.1007/s00066-013-0549-1CrossRefPubMedGoogle Scholar
  49. Kouloulias V, Plataniotis G, Kouvaris J, Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C, Vlahos L (2005) Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 28(1):91–99CrossRefPubMedGoogle Scholar
  50. Kurian A, Suryadevara S, Ramaraju D, Gallagher S, Hofmann M, Kim S, Zebley M, Fassler S (2011) In-hospital and 6-month mortality rates after open elective vs open emergent colectomy in patients older than 80 years. Dis Colon Rectum 54(4):467–471.  https://doi.org/10.1007/DCR.0b013e3182060904, [pii] 00003453-201104000-00012CrossRefPubMedGoogle Scholar
  51. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372(26):2509–2520.  https://doi.org/10.1056/NEJMoa1500596CrossRefPubMedPubMedCentralGoogle Scholar
  52. Lorimer PD, Motz BM, Kirks RC, Boselli DM, Walsh KK, Prabhu RS, Hill JS, Salo JC (2017) Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the national cancer database. Ann Surg Oncol 24(8):2095–2103.  https://doi.org/10.1245/s10434-017-5873-8CrossRefPubMedGoogle Scholar
  53. Louis DJ, Hsu A, Brand MI, Saclarides TJ (2009) Morbidity and mortality in octogenarians and older undergoing major intestinal surgery. Dis Colon Rectum 52(1):59–63.  https://doi.org/10.1007/DCR.0b013e31819754d4, [pii] 00003453-200901000-00010CrossRefPubMedGoogle Scholar
  54. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909–1919.  https://doi.org/10.1056/NEJMoa1414325CrossRefPubMedGoogle Scholar
  55. McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O’Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 31(20):2600–2606.  https://doi.org/10.1200/JCO.2013.49.6638CrossRefPubMedPubMedCentralGoogle Scholar
  56. Mitry E, Bouvier AM, Esteve J, Faivre J (2005) Improvement in colorectal cancer survival: a population-based study. Eur J Cancer 41(15):2297–2303.  https://doi.org/10.1016/j.ejca.2005.01.028, [pii] S0959-8049(05)00564-2CrossRefPubMedGoogle Scholar
  57. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andre T (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol.  https://doi.org/10.1016/S1470-2045(17)30422-9PubMedGoogle Scholar
  58. Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Kohne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M (2015) Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26(3):463–476.  https://doi.org/10.1093/annonc/mdu253CrossRefPubMedGoogle Scholar
  59. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17(8):2412–2418.  https://doi.org/10.1200/JCO.1999.17.8.2412CrossRefPubMedGoogle Scholar
  60. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heussner P, Hohenberger W, Holstege A, Hubner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W (2013) S3-guideline colorectal cancer version 1.0. Z Gastroenterol 51(8):753–854.  https://doi.org/10.1055/s-0033-1350264CrossRefPubMedGoogle Scholar
  61. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 23(6):1531–1536.  https://doi.org/10.1093/annonc/mdr488CrossRefPubMedGoogle Scholar
  62. Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Van Cutsem E, Lutz MP, Nordlinger B (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10):2619–2626.  https://doi.org/10.1093/annonc/mds053CrossRefPubMedPubMedCentralGoogle Scholar
  63. Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA (2008) Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9(5):494–501.  https://doi.org/10.1016/S1470-2045(08)70129-3CrossRefPubMedGoogle Scholar
  64. Sanoff HK, Carpenter WR, Sturmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D (2012) Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30(21):2624–2634.  https://doi.org/10.1200/JCO.2011.41.1140CrossRefPubMedPubMedCentralGoogle Scholar
  65. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097.  https://doi.org/10.1056/NEJMoa010957CrossRefPubMedGoogle Scholar
  66. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25(29):4569–4574.  https://doi.org/10.1200/JCO.2006.10.4323CrossRefPubMedGoogle Scholar
  67. Sastre J, Aranda E, Gravalos C, Massuti B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Diaz-Rubio E, Hidalgo M (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77(1):78–84.  https://doi.org/10.1016/j.critrevonc.2009.11.005, [pii] S1040-8428(09)00229-7CrossRefPubMedGoogle Scholar
  68. Sastre J, Massuti B, Pulido G, Guillen-Ponce C, Benavides M, Manzano JL, Reboredo M, Rivera F, Gravalos C, Safont MJ, Martinez Villacampa M, Llovet P, Dotor E, Diaz-Rubio E, Aranda E (2015) First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. Eur J Cancer 51(11):1371–1380.  https://doi.org/10.1016/j.ejca.2015.04.013, [pii] S0959-8049(15)00349-4CrossRefPubMedGoogle Scholar
  69. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C (2003) Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14(12):1735–1743CrossRefPubMedGoogle Scholar
  70. Schiffmann L, Klautke G, Wedermann N, Gock M, Prall F, Fietkau R, Rau B, Klar E (2013) Prognosis of rectal cancer patients improves with downstaging by intensified neoadjuvant radiochemotherapy – a matched pair analysis. BMC Cancer 13:388.  https://doi.org/10.1186/1471-2407-13-388CrossRefPubMedPubMedCentralGoogle Scholar
  71. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG (2015) Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol.  https://doi.org/10.1200/JCO.2015.60.9107PubMedCentralGoogle Scholar
  72. Schrag D (2016) The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol 34 (suppl; abstr 3505)Google Scholar
  73. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY (2014) PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247.  https://doi.org/10.1200/JCO.2013.53.2473CrossRefPubMedGoogle Scholar
  74. Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS 2): an open-label, randomised factorial trial. Lancet 377(9779):1749–1759.  https://doi.org/10.1016/S0140-6736(11)60399-1CrossRefPubMedPubMedCentralGoogle Scholar
  75. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508.  https://doi.org/10.1016/S1470-2045(15)70127-0CrossRefPubMedGoogle Scholar
  76. Takeda A, Sanuki N, Kunieda E (2014) Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol 20(15):4220–4229.  https://doi.org/10.3748/wjg.v20.i15.4220CrossRefPubMedPubMedCentralGoogle Scholar
  77. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V (2016) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2016.37972565703Google Scholar
  78. Thermann P, Seufferlein T (2010) Aktuelle Therapie des Kolonkarzinoms. Der Gastroenterologe 5(1):57–71.  https://doi.org/10.1007/s11377-009-0387-yCrossRefGoogle Scholar
  79. Toh JW, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ (2016) The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer 15(4):285–291.  https://doi.org/10.1016/j.clcc.2016.07.007, [pii] S1533-0028(16)30108-6CrossRefPubMedGoogle Scholar
  80. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D’Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580.  https://doi.org/10.1200/JCO.2007.11.0833, [pii] 25/29/4575CrossRefPubMedGoogle Scholar
  81. Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30(27):3353–3360.  https://doi.org/10.1200/JCO.2012.42.5645CrossRefPubMedGoogle Scholar
  82. Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Diaz-Rubio E, Gilberg F, Cassidy J (2012) Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23(5):1190–1197.  https://doi.org/10.1093/annonc/mdr366CrossRefPubMedGoogle Scholar
  83. Yamano T, Yamauchi S, Kimura K, Babaya A, Hamanaka M, Kobayashi M, Fukumoto M, Tsukamoto K, Noda M, Tomita N, Sugihara K (2017) Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: a retrospective multicentre study. Eur J Cancer 81:90–101.  https://doi.org/10.1016/j.ejca.2017.05.024, [pii] S0959-8049(17)30979-6CrossRefPubMedGoogle Scholar
  84. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29(28):3768–3774.  https://doi.org/10.1200/JCO.2011.36.4539CrossRefPubMedPubMedCentralGoogle Scholar
  85. Zee J van der, Gonzalez GD (2002) The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 18(1):1–12Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Nicolai Härtel
    • 1
  • Gunther Klautke
    • 2
  • Ulrich Ronellenfitsch
    • 3
  1. 1.II. Medizinische Klinik, Universitätsmedizin MannheimMannheim und Abt. Gastroenterologie und Onkologie, Heilig-Geist Hospital BensheimBensheimDeutschland
  2. 2.Klinik und Praxis für RadioonkologieKlinikum ChemnitzChemnitzDeutschland
  3. 3.Klinik für Gefäßchirurgie und Endovaskuläre ChirurgieUniversitätsklinikum HeidelbergHeidelbergDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations